Targeting the Resistance in Multiple Myeloma
Multiple myeloma is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. That disease has a rather low incidence but displays a high rate of relapse and resistance to conventional therapies. It is therefore necessary to find new therapeutic s...
Main Authors: | Micaela Freitas, Mark E. Issa, Muriel Cuendet |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | Proceedings |
Subjects: | |
Online Access: | https://www.mdpi.com/2504-3900/11/1/3 |
Similar Items
-
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
by: Jennifer Sun, et al.
Published: (2020-01-01) -
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
by: Gül Kozalak, et al.
Published: (2023-01-01) -
Entinostat-Bortezomib Hybrids against Multiple Myeloma
by: Angelica Ferro, et al.
Published: (2023-02-01) -
Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma
by: Hamed Bashiri, et al.
Published: (2023-03-01) -
Anaplastic morphology in IgD multiple myeloma
by: Verónica Roldán Galiacho, et al.
Published: (2023-10-01)